It appears that Johnson & Johnson likes the American court system, but only when they are the Plaintiff in a lawsuit asking for money damages. Recently, a federal court jury returned a $1.67 billion verdict for J&J against Abbott Laboratories in a patent infringement suit over the company’s rheumatoid arthritis drugs. Abbott’s best-selling drug, Humira, competes with the drug Remicade, made by Centocor, a unit of J&J.
In 2007, J&J Centocor and New York University filed a patent infringement suit against Abbott in a Texas federal court. As you may know, Humira has been an instrumental part of Abbott’s success story in recent years, gaining approvals for half a dozen uses, including psoriasis and Crohn’s disease. Abbott had $4.5 billion in Humira sales in 2008. This verdict is being viewed as a major victory for J&J.
Source: Lawyers USA Online
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.